IM Inj in deltoid region. Subjects ≥15 yr Three 0.5 mL doses at 0, 1, 6 mth (2nd dose can be administered between 1 & 2.5 mth after 1st dose & 3rd dose between 5 & 12 mth after 1st dose), 9-14 yr Two 0.5 mL doses w/ 2nd dose given between 5 & 13 mth after 1st dose (if 2nd dose is administered before the 5th mth after 1st dose, a 3rd dose should always be administered) or three 0.5 mL doses at 0, 1, 6 mth (2nd dose can be administered between 1 & 2.5 mth after 1st dose & 3rd dose between 5 & 12 mth after 1st dose).
Postpone vaccination in case of acute severe febrile illness. Not intended to prevent progression of HPV-related lesions present at the time of vaccination or provide protection against all oncogenic HPV types. Not a substitute for regular cervical screening or against exposure to HPV & STD. Not to be administered intravascularly or intradermally. Syncope. Thrombocytopenia or any coagulation disorder. Immunocompromised patients. Perform review of medical history & clinical exam before vaccination. Postpone vaccination until completion of pregnancy. Lactation.
Sign Out
b77cd649-b6c0-44a2-8278-a5cb0135d6a4.GIF)
